Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;79(2):290-298.
doi: 10.1177/10775587211004311. Epub 2021 Apr 1.

The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill

Affiliations

The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill

Thuy Nguyen et al. Med Care Res Rev. 2022 Apr.

Abstract

This article examines the relationship between federal regulations, state scope-of-practice regulations on nurse practitioners (NPs), and buprenorphine prescribing patterns using pharmacy claims data from Optum's deidentified Clinformatics Data Mart between January 2015 and September 2018. The county-level proportion of patients filling prescriptions written by NPs was low even after the 2016 Comprehensive Addiction and Recovery Act (CARA), 2.7% in states that did not require physician oversight of NPs, and 1.1% in states that did. While analyses in rural counties showed higher rates of buprenorphine prescriptions written by NPs, rates were still considerably low: 3.7% in states with less restrictive regulations and 1.1% in other states. These results indicate that less restrictive scope-of-practice regulations are associated with greater NP prescribing following CARA. The small magnitude of the changes indicates that federal attempts to expand treatment access through CARA have been limited.

Keywords: Comprehensive Addiction and Recovery Act; buprenorphine prescribing; nurse practitioners; scope-of-practice regulations.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: No known conflicts of interest for any.

Figures

Figure 1:
Figure 1:. Buprenorphine Prescribing by NPs in Less Restrictive States Vs. More Restrictive States, 2015Q1 – 2018Q3
Source/Notes: Authors’ calculations of county-level proportion of patients who filled buprenorphine prescriptions written by NPs based pharmacy claims data from the 100% controlled substance universe of Optum’s de-identified Clinformatics® Data Mart Database 2015Q1 to 2018Q3. 2016Q3 is the implementation quarter of CARA 2016. The orange and blue lines show the mean proportion of patients who filled buprenorphine prescriptions written by NPs per quarter. The red dashed line is the aggregate number of individuals (national level) who filled any buprenorphine prescriptions per quarter. Error bars present the 95% CIs.
Figure 2:
Figure 2:. Antibiotic and NSAID Prescribing by NPs in Less Restrictive States Vs. More Restrictive States, 2015Q1 – 2018Q3
Source/Notes: Authors’ calculations of county-level proportion of patients who filled NSAID or antibiotic prescriptions written by NPs based pharmacy claims data from the 100% controlled substance universe of Optum’s de-identified Clinformatics® Data Mart Database 2015Q1 to 2018Q3. The red and navy lines show the mean proportion of patients who filled prescriptions written by NPs per quarter. The gray dashed line is the aggregate number of individuals (national level) who filled any relevant prescription per quarter. Error bars present the 95% CIs.

References

    1. The SUPPORT for Patients and Communities Act, (2018). https://www.congress.gov/bill/115th-congress/house-bill/6
    1. Andraka-Christou B, & Capone MJ (2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. International Journal of Drug Policy, 54, 9–17. 10.1016/j.drugpo.2017.11.021 - DOI - PubMed
    1. Andrilla CHA, Moore TE, Patterson DG, & Larson EH (2018). Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. The Journal of Rural Health, 0, 1–5. 10.1111/jrh.12307 - DOI - PubMed
    1. Andrilla CHA, Patterson DG, Moore TE, Coulthard C, & Larson EH (2018). Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review, 1077558718793070. - PubMed
    1. Auty SG, Stein MD, Walley AY, & Drainoni M-L (2020). Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply. Journal of Substance Abuse Treatment, 108032. - PMC - PubMed

Publication types